Targeting metaplasticity mechanisms to promote sustained antidepressant actions

KA Brown, TD Gould - Molecular psychiatry, 2024 - nature.com
The discovery that subanesthetic doses of (R, S)-ketamine (ketamine) and (S)-ketamine
(esketamine) rapidly induce antidepressant effects and promote sustained actions following …

[HTML][HTML] One path, two solutions: Network-based analysis identifies targetable pathways for the treatment of comorbid type II diabetes and neuropsychiatric disorders

A Onisiforou, P Zanos - Computational and Structural Biotechnology …, 2024 - Elsevier
Comorbid diseases complicate patient outcomes and escalate healthcare costs,
necessitating the need for a deeper mechanistic understanding. Neuropsychiatric disorders …

Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies

B Chruścicka-Smaga, A Machaczka, B Szewczyk… - Pharmacological …, 2023 - Springer
The desire to find a gold-standard therapy for depression is still ongoing. Develo** one
universal and effective pharmacotherapy remains troublesome due to the high complexity …

(2R,6R)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice

A Michael, A Onisiforou, P Georgiou, M Koumas… - bioRxiv, 2023 - biorxiv.org
Opioid addiction is a pressing public health concern marked by frequent relapse during
periods of abstinence, perpetuated by negative affective states and anhedonia-driven …

[HTML][HTML] Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders

A Onisiforou, A Michael, M Apostolakis… - Biological …, 2024 - Elsevier
Opioid use disorder (OUD) has reached epidemic proportions, with many countries facing
high levels of opioid use and related fatalities. Although currently prescribed medications for …

Network-Based Analysis Identifies Targetable Pathways in Comorbid Type II Diabetes and Neuropsychiatric Disorders

A Onisiforou, P Zanos - bioRxiv, 2024 - biorxiv.org
Comorbid diseases complicate patient outcomes and escalate healthcare costs,
necessitating a deeper mechanistic understanding. Neuropsychiatric disorders (NPDs) such …

Ketamine and hydroxynorketamine as novel pharmacotherapies for the treatment of Opioid-Use Disorders

O Anna, A Michael, M Apostolakis… - Biological … - biologicalpsychiatryjournal.com
Opioid use disorder (OUD) has reached epidemic proportions, with many countries facing
high opioid use and related fatalities. Although currently-prescribed medications for OUD …

[SITAT][C] Role of mGlu receptors in psychiatric disorders-Recent Advances.

A Pilc, S Chaki - Pharmacology, Biochemistry, and Behavior, 2023 - europepmc.org
Role of mGlu receptors in psychiatric disorders -Recent Advances. - Abstract - Europe PMC Sign
in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …